



CONFÉRENCE DU LUNDI MIDI

Programme en santé de l'enfant et en développement humain



THOMAS KITZLER, MD, FRCPC

Professeur adjoint, Département de génétique humaine de l'Université McGill, Généticien clinique, Division de génétique médicale, Scientifique junior, Programme en santé de l'enfant et en développement humain (Centre de la biologie translationnelle), IR-CUSM

16 MARS de 12h à 13h

IR-CUSM, BLOC E

L'AMPHITHÉÂTRE CRUESS, SALLE S1.1129

1001, boul. Decarie, Montréal (Québec) H4A 3J1

La maladie rénale à l'ère de la médecine génomique

Chronic kidney disease affects one out of ten Canadians. While genetic causes are individually rare, their combined disease burden is significant. The current mainstay of treating patients with end-stage renal disease is associated with significant patient morbidity and mortality, while exerting a strenuous cost on the health care system. This highlights the need for new strategies and tools for the identification of patients at risk for disease prevention, as well as, for novel treatment approaches for patients with renal failure. Genomic diagnostic tools combined with new technologies, such as CRISPR/Cas9 gene editing and single-cell RNA sequencing, have led to a rapid increase in our understanding of the genetic contribution to kidney disease, while enabling the identification of novel targets for personalized treatment approaches. We will discuss how genetic information has already benefited patient care, but also how current research can address some of the remaining challenges to the successful implementation of genomic information in management of chronic kidney disease.